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Abstract Portal vein thrombosis may occur in cirrhosis;
nevertheless, its prevalence, and predictors are still elusive.
To investigate this issue, the Italian Society of Internal
Medicine undertook the ‘‘Portal vein thrombosis Relevance
On Liver cirrhosis: Italian Venous thrombotic Events
Registry’’ (PRO-LIVER). This prospective multicenter
study includes consecutive cirrhotic patients undergoing
Doppler ultrasound examination of the portal area to
evaluate the prevalence and incidence of portal vein
thrombosis over a 2-year scheduled follow-up. Seven
hundred and fifty-three (68 % men; 64 ± 12 years)
patients were included in the present analysis. Fifty percent
of the cases were cirrhotic outpatients. Viral (44 %) eti-
ology was predominant. Around half of the patients had a
mild-severity disease according to the Child–Pugh score;
hepatocellular carcinoma was present in 20 %. The
prevalence of ultrasound-detected portal vein thrombosis
was 17 % (n = 126); it was asymptomatic in 43 % of the
cases. Notably, more than half of the portal vein throm-
bosis patients (n = 81) were not treated with anticoagulant
therapy. Logistic step-forward multivariate analysis
demonstrated that previous portal vein thrombosis
(p\ 0.001), Child–Pugh Class B ? C (p\ 0.001), hepa-
tocellular carcinoma (p = 0.01), previous upper gastroin-
testinal bleeding (p = 0.030) and older age (p = 0.012)
were independently associated with portal vein thrombosis.
Portal vein thrombosis is a frequent complication of cir-
rhosis, particularly in patients with moderate–severe liver
failure. The apparent undertreatment of patients with portal
vein thrombosis is a matter of concern and debate, which
should be addressed by planning interventional trials
especially with newer oral anticoagulants.
Clinicaltrials.gov identifier NCT01470547.
Keywords Splanchnic venous thrombosis 
Anticoagulants  Liver failure  Hepatocellular carcinoma 
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Introduction
For decades, cirrhosis patients have been considered at risk
of bleeding complications, which were believed to stem
from impaired clotting activation coincidentally with
deterioration of liver function. However, the term ‘‘coag-
ulopathy’’, which has been coined to indicate the
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association between clotting changes and bleeding [1], has
been recently challenged because, apart from gastroin-
testinal (GI) variceal bleeding, which is generally unrelated
to clotting changes, bleeding complications in cirrhosis are
rare [2]. Conversely, a large body of evidences has been
accumulating to indicate an association between throm-
bosis and cirrhosis, particularly in patients with decom-
pensated disease [3]; thrombosis may occur in the portal
vein (portal vein thrombosis, PVT) or systemic circulation
[4–7].
Cirrhosis is the underlying cause of PVT in 22–28 % of
all cases [3]. The prevalence of PVT in cirrhosis is variable
depending on the diagnostic procedure and on the degree of
liver failure. In angiography or surgery studies, the
prevalence of PVT ranges from 0.6 to 16 %; using ultra-
sonography, the reported prevalence is as high as 10–25 %
[3]. The prevalence of PVT also increases with the severity
of cirrhosis, being approximately 1 % in patients with
compensated cirrhosis and rising to 8–25 % in candidates
for liver transplantation [3]. Important limitations of most
past studies of PVT in cirrhosis include their retrospective
design and the small sample size, making it difficult to
draw firm conclusions. Furthermore, if detection is based
solely on the presence of overt symptoms, PVT may be
underestimated, as it is often first detected in asymptomatic
patients. Its significance in this setting remains a point of
debate, but can be better understood with complete and
more definitive knowledge of its prevalence and incidence.
Clinical and laboratory predictors of PVT are also still
unclear. Among the local factors, decreased portal flow
velocity and coexistent hepatocellular carcinoma (HCC)
were frequently observed [8–10]. Recently, in a post hoc
analysis of THROMBOCIR study, among 1243 Child–
Pugh A and B cirrhotic patients, the baseline risk factors
independently associated with PVT were esophageal vari-
ces and prothrombin time (PT) [11]; however, the predic-
tors of PVT in the real world of cirrhosis including a wider
range of liver failure severity are still elusive.
To further study the PVT prevalence and risk factors
related to it, the Italian Society of Internal Medicine (SIMI)
designed a registry exploring PVT prevalence in the day to
day world of cirrhosis management and included patients
with different degrees of liver failure as classified by
Child–Pugh or MELD score [12, 13]. The ‘‘Portal vein
thrombosis Relevance On Liver cirrhosis: Italian Venous
thrombotic Events Registry’’ (PRO-LIVER) study started
in January 2012. The specific aim of the present analysis
from the PRO-LIVER registry was to estimate the preva-
lence of PVT, as detected by upper abdominal Doppler
ultrasonography (US) examination and to depict the clini-
cal independent factors associated with PVT presence in
cirrhosis.
Methods
Study design
The PRO-LIVER study is an ongoing Italian-based
prospective multicenter study with the primary objective of
estimating the prevalence of PVT in a cohort of patients
with cirrhosis of any etiology and severity.
As secondary end points, it was planned that the yearly
evaluation over the 2-year follow-up would include the
following events: (1) venous thrombotic events [i.e., deep
vein thrombosis/pulmonary embolism (VTE) and PVT];
(2) bleeding events (i.e., GI or non-GI hemorrhage); (3)
overall mortality; (4) hospital admissions for decompen-
sated cirrhosis and (5) occurrence of cirrhosis-related
complications (i.e., onset or progression of esophageal
varices, ascites or refractory ascites, jaundice, onset of liver
cancer, infections, spontaneous bacterial peritonitis, onset
of hepato-renal or hepatic–pulmonary syndrome).
The SIMI coordinates all regional centers (see Online
Appendix 1) involved in the study, having the same stan-
dard of care, by the creation of a network for the recruit-
ment and monitoring of cirrhotic patients.
This study was conducted in accordance with the EU
Note for Guidance on Good Clinical Practice CPMP/ECH/
135/95 and the Declaration of Helsinki. Informed consent
was obtained from all individual participants included in
the study. The study was initiated only after local and ethic
approval requirements were obtained (ClinicalTrials.gov
Identifier: NCT01470547). The center’s participation in the
registry was voluntary and not sponsored.
Study population
All consecutive cirrhotic patients who were referred to the
43 participating centers (n = 33 internal medicine units;
n = 10 hepatology units) were enrolled. The presence of
concomitant extra-hepatic neoplasms was the only exclu-
sion criteria. Thus, we included patients with a diagnosis of
cirrhosis of any etiology and severity (including cirrhosis
complicated by HCC).
At baseline, complete medical history, thrombosis risk fac-
tor evaluation, anthropometric data and evaluation of the
severity of cirrhosis were registered. The Child–Pugh score [12]
and MELD score [13] were assessed to establish the severity of
liver disease. In addition, the state of liver disease compensation
was reported according to Baveno IV score [14].
Among laboratory variables, only prothrombin time, total
bilirubin, serum albumin and serum creatinine were
mandatory to allow the Child–Pugh and MELD calculation.
However, additional laboratory parameters could be inserted
in the standard form at discretion of the investigator.
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Doppler ultrasound examination
A Doppler US examination of the portal vein main trunk
and its branches and tributaries was mandatory to evaluate
the presence of PVT. Standard US parameters that were
assessed included the presence or absence of focal liver
lesions, the spleen diameter and a complete evaluation of
the portal vein axis and were reported on a standardized
form (see Online Appendix 2). If available, portal vein flow
velocity was also recorded.
Portal vein thrombosis: definition
By pre-set study criteria, PVT was first suspected when
solid endoluminal material was detected in the main trunk
of the portal vein and/or its branches, and it was confirmed
by demonstration of a filling defect on Doppler examina-
tion. Occlusive/complete PVT was defined by a thrombus
leaving no channel for blood flow. Otherwise, PVT was
considered to be non-occlusive/incomplete. The definition
of previous PVT was reported by investigators as a positive
clinical history of PVT. For all patients with previous PVT,
we requested to provide instrumental information to sup-
port this previous event (i.e., instrumental demonstration of
PVT resolution) and to validate PVT recurrence.
Data collection and validation
In each center, data were collected using an electronic case
report form (CRF: http://www.simi.it/attivita/ricerca/PRO
LIVER/). Data were transferred to the web-central database
(Coordination Center-I Clinica Medica, Sapienza-Univer-
sity of Rome). Using a validation plan integrated in the
data entry software, data were checked for missing or
contradictory entries and values out of the normal range. A
final database was created and validated by the study
coordinators (see Online Appendix 1). Patient’s identifi-
cation name was registered in the participating centers, but
was not transferred to the central database. Patients were
identified by a serial number for each center.
Sample size determination
We originally planned to include in the study n = 1100
patients. After 36 months of enrollment, the Data and
Safety Monitoring Board (see Online Appendix 1) decided
to terminate the trial due to insufficient accrual rate. This
decision was taken before any data disclosure and therefore
had no impact on the estimates other than a slightly larger
expected confidence interval. The trial was terminated,
considering that the current sample size would guarantee,
assuming (as originally planned) an expected prevalence of
18 % at time zero, a 95 % confidence interval with a width
less than or equal to 5.3 %. This width was deemed to be
satisfactory and the trial was terminated.
Statistical analysis
All continuous variables were tested for normality with the
Shapiro–Wilk test. Variables with normal distribution were
expressed as mean and standard deviation and tested for
differences with the Student’s t test. Non-normal variables
were expressed as median and interquartile range (IQR)
and differences tested with the Mann–Whitney U test.
Categorical variables were expressed as counts and per-
centages and analyzed by a Chi-square test.
A logistic regression analysis was performed to establish
all clinical factors significantly associated with PVT pres-
ence. All variables entered the multivariate logistic model;
a forward stepwise method was used to build the final
model. A two-sided p value \0.05 was considered to be
statistically significant. All analyses were performed using
SPSS v. 22.0 (IBM, NY, USA).
Results
From January 2012 to December 2014, among 43 enrolling
units, a total of 802 consecutive cirrhotic patients were
enrolled. Two participant centers, which globally recruited
49 patients, were excluded from the analysis for a selection
bias, as they enrolled only patients with PVT. Therefore,
753 consecutive cirrhotic patients were included in the
present analysis (Fig. 1). Approximately, 50 % of the cases
were outpatients.
Patients
The overall mean age was 64 ± 12 years and 68 % were
men. Viral (44 %) or alcoholic (25 %) etiologies were
predominant. Around half of the patients (47 %) had a
Fig. 1 Flow chart of the study. PVT portal vein thrombosis
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moderate–severe disease according to Child–Pugh score
(i.e., classes B or C) and similarly compensated cirrhosis
was evident in over half (57 %) according to the Baveno
IV score. HCC was detected in 20 %. Seventeen patients
had an inserted transjugular intrahepatic portosystemic
shunt prior to study entry.
PVT was detected in 126 patients (17 %), with occlu-
sion only in the main trunk or its branches in 81 patients
(64 %), while obstruction of more than one portal vein
branches was present in 45 patients (36 %); an extension of
thrombosis to the mesenteric–splenic veins was reported in
27 patients (21 %). According to Yerdel grade [15], PVT in
our cohort was classified as follows: 60 % grade I, 19 %
grade II and 21 % grade III–IV. A non-occlusive/incom-
plete PVT was present in 95 % of the cases, independent of
the site of thrombosis. In the 40 % of patients with US-
detected PVT (n = 49), CT or MRI was also performed to
confirm the diagnosis.
PVT was asymptomatic in 54 patients (43 %). The
clinical manifestations of PVT was in 51 % of the cases
ascites not responsive to diuretics requiring paracentesis, in
5 patients (4 %) an upper gastrointestinal bleeding and in 2
patients an episode of acute encephalopathy (2 %).
Comparison of PVT with non-PVT
Clinical and laboratory characteristics of patients according
to the presence or absence of PVT are depicted in Table 1.
Cirrhotic patients with PVT were older (67 ± 11 years)
and more frequently inpatients (59 %) as opposed to the
outpatient setting (41 %). No differences in etiology, sex
and body mass index were observed. Cirrhotic patients
with PVT showed a more advanced and decompensated
disease with higher prevalence of Child–Pugh B and C
classes (p\ 0.0037). Furthermore, the presence of ascites
and encephalopathy, as well as diuretic treatment was more
frequently observed in PVT patients.
Detection of esophageal varices of grade C2 (39 %), as
well as the presence of indirect US signs of portal hyper-
tension, such as increases of portal vein diameter and
splenomegaly, characterized PVT patients. Compared with
patients without PVT, PVT patients had an increased
bipolar spleen diameter (15 ± 3 vs. 14 ± 3, p = 0.0072).
HCC prevalence was 35 % in patients with PVT versus
17 % in those without PVT. PVT patients had a clinical
history more complicated by previous PVT (20 %,
p\ 0.0001) and upper GI bleeding (24 %, p = 0.0075).
Among the laboratory parameters, only serum albumin and
platelet count differed between patients with and without
PVT (Table 1).
Eighty-one out of 126 PVT patients (64 %) did not
receive any anticoagulant treatment; among PVT on
treatment with anticoagulants, 33 were being treated with
low molecular weight heparins, 7 with fondaparinux and 5
with warfarin.
Table 2, panel A, reported variables significantly asso-
ciated with PVT on univariate analysis. All these variables
entered the multivariate logistic analysis. The final model
(Table 2, panel b) showed that previous PVT (p\ 0.001),
Child–Pugh class B ? C (p\ 0.001), HCC (p = 0.01),
previous upper GI bleeding (p = 0.030) and older age
(p = 0.012) were significantly associated with the presence
of PVT.
Discussion
In this large multicenter study, we demonstrate that PVT is
a frequent complication of cirrhosis with about one-fifth of
patients suffering from this vascular complication; older
patients with more severe liver failure were at higher risk
of PVT.
The present study supports and extends previous find-
ings on this topic indicating that thrombosis may frequently
occur in cirrhosis whatever is its etiology. This complica-
tion is biologically plausible, as previously shown by the
demonstration of an ongoing prothrombotic state in the
portal vein of cirrhotic patients undergoing transjugular
intrahepatic portosystemic shunt [16]; of note, markers of
clotting activation were also detected in the peripheral
circulation of cirrhotic patients compared to controls [17].
Among the mechanisms potentially accounting for PVT,
there is experimental and clinical evidence that bacterial
endotoxins such as lipopolysaccharide (LPS) may predis-
pose to thrombosis [18]. Thus, patients with cirrhosis show
an increased concentration of bacterial endotoxins in the
portal and systemic circulation compared to controls [16,
17]. This ‘‘low-grade’’ endotoxemia is related to translo-
cation of bacteria and bacteria products (such as endotoxins
from intestinal lumen to the portal circulation) and to
endotoxin spillover into systemic circulation [19]. Toge-
ther, these data led us to hypothesize that low-grade
endotoxemia might favor thrombosis; in support of this,
experimental and clinical studies demonstrated that in
cirrhosis, endotoxemia affects Virchow’s triad, i.e.,
hypercoagulation, endothelial damage and reduced flow
velocity, which are crucial for thrombus formation [18, 20,
21].
Among the factors associated with PVT, age and liver
failure seem to have a prominent role; thus, older patients
and those with moderate–severe liver failure are those in
whom PVT is more prevalent. This more frequent associ-
ation may be explained by the fact that the ongoing pro-
thrombotic state is more frequent in patients of Child–Pugh
classes B and C compared to class A [15, 22, 23]. Another
novel finding of the study is that patients with PVT have a
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Table 1 Distribution variables
according to the presence of
PVT
Variables Patients without PVT
(n = 627)
Patients with PVT
(n = 126)
p
Age (mean ± SD) 64 ± 12 67 ± 11 0.0047
Male sex, n (%) 432 (69) 81 (64) 0.3105
BMI (kg/m2) 26 ± 4 26 ± 5 0.2746
Inpatients, n (%) 283 (45) 75 (59) 0.0031
Etiology 0.6681
Alcohol, n (%) 149 (24) 37 (29)
Viral, n (%) 274 (44) 58 (46)
NASH/metabolic, n (%) 38 (6) 5 (4)
Autoimmune, n (%) 15 (2) 3 (2)
Mixed, n (%) 89 (14) 13 (10)
Others/unknown, n (%) 62 (10) 10 (8)
Child–Pugh Score 0.0037
Class A, n (%) 352 (56) 45 (37)
Class B, n (%) 194 (31) 64 (50)
Class C, n (%) 81 (13) 17 (13)
Child–Pugh Score, median [IQR] 6 [5–8] 7 [6–9] 0.1129
Meld Score, median [IQR] 10 [8–13] 12 [10–14] 0.0216
Baveno Score 0.0004
Compensated, n (%) 387 (62) 51 (41)
Decompensated, n (%) 240 (38) 75 (59)
Previous thrombotic events
Previous portal vein thrombosis, n (%) 26 (4) 26 (20) \0.0001
Previous VTE, n (%) 12 (2) 4 (3) 0.8451
Bleeding GI events
Upper GI bleeding, n (%) 33 (5) 5 (4) 0.5537
Previous upper GI bleeding, n (%)a 89 (15) 30 (24) 0.0075
Lower GI bleeding, n (%) 10 (2) 4 (3) 0.2309
Previous lower GI bleeding, n (%)b 33 (5) 8 (6) 0.6060
Esophageal varices, n (%)c 0.0015
NO, n (%) 200 (42) 25 (24)
F1, n, (%) 177 (37) 39 (37)
F2, n (%) 85 (18) 29 (28)
F3, n (%) 17 (3) 11 (11)
Ascites 0.00018
NO, n (%) 407 (65) 57 (45)
Responsive, n (%) 164 (26) 53 (42)
Refractory, n (%) 56 (9) 16 (13)
Encephalopathy 0.0187
NO, n (%) 540 (86) 96 (76)
Mild, n (%) 77 (12) 27 (21)
Moderate–severe, n (%) 10 (2) 3 (2)
Presence of concomitant HCC, n (%) 108 (17) 44 (35) \0.0001
Albumin (gr/L) 3.4 ± 0.6 3.1 ± 0.6 \0.0001
Bilirubin (mg/dL) 2.0 ± 2.8 2.6 ± 4.3 0.0508
PT-INR 1.29 ± 0.34 1.33 ± 0.23 0.3040
Creatinine (mg/dL) 0.95 ± 0.65 0.97 ± 0.39 0.7450
Platelet count (9109/L)d 116 ± 68 103 ± 58 0.0491
Diuretics, n (%)
Aldosterone receptor antagonist 330 (53) 80 (63) 0.0255
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more frequent history of prior PVT. This finding is of
interest as it shows that cirrhotic patients with PVT are at
higher risk of recurrence and possibly should be treated to
prevent it. So far, however, such perception as well as the
need of treating cirrhotic PVT patients with anticoagulants
seems to be weak; thus,[50 % of cirrhotic patients with
PVT were not treated with anticoagulant despite some
evidence of clinical benefit from the use of anti-thrombotic
drugs in this specific setting [24, 25]. This underuse is
likely dependent on the persistent concept of ‘‘coagulopa-
thy in cirrhosis’’, which may be a barrier against the use of
anticoagulants in cirrhotic patients with PVT [26], the
ongoing debate regarding the clinical significance of PVT
and whether or not it is clinically significant or represents
an epiphenomenon of advanced liver disease.
Another factor independently associated with PVT is
upper GI bleeding, which is likely a mirror of the portal
hypertension associated with PVT and, hence, reflects the
already recognized higher risk of bleeding in cirrhotic
patients with PVT [2, 21].
The study has limitations and implications. The cross-
sectional nature of the study does not allow prospectively
analyzing PVT predictors and incidence in the cirrhotic
population; the follow-up, currently ongoing in the PRO-
LIVER study, will be useful to evaluate these issues. The
study has been done in a Caucasian population; there-
fore, our findings cannot be extrapolated to other popu-
lations. The validation of the PVT using a CT scan would
be useful, but was not requested by the protocol. How-
ever, the standardization of US parameters should guar-
antee the quality of the imaging data collection. The low
rate of recruitment per center, despite no restrictive
patient inclusion criteria, could be explained by the
predominant involvement of an internal medicine ser-
vices network. Patients with moderate to severe liver
failure are at high risk of PVT and should be routinely
screened for PVT even in the absence of specific symp-
toms, particularly in older patients or with a previous
history of PVT. However, we did not investigate if the
clinical history was complicated by deep venous throm-
bosis, which seems to complicate the clinical course of
cirrhosis.
In conclusion, PVT is a frequent complication of cir-
rhosis, particularly in patients with moderate–severe liver
failure. The significance of the condition remains a matter
of debate, but in our opinion undertreatment of patients
with PVT is a persistent matter of concern, which should be
addressed by planning interventional trials with old or new
oral anticoagulants.
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Table 1 continued
Variables Patients without PVT
(n = 627)
Patients with PVT
(n = 126)
p
Loop diuretics, n (%) 315 (50) 79 (63) 0.0106
Beta-blockers, n (%) 277 (51) 67 (59) 0.1412
a Data recorded in 731 patients
b Data recorded in 741 patients
c Data recorded in 583 patients
d Data available in 753 patients
Table 2 Univariate analysis (Panel A) and logistic multivariate
analysis (final model, Panel B)
Variables OR 95 % CI p values
Panel A
Age 1.02 1.00–1.04 0.005
Inpatients 1.78 1.21–2.64 0.003
Child–Pugh B ? C 2.21 1.49–3.28 \0.0001
Decompensated cirrhosis 2.43 1.64–3.60 \0.0001
Ascites 2.23 1.52–3.29 \0.0001
Encephalopathy 1.94 1.21–3.09 0.006
Previous PVT 6.01 3.35–10.77 \0.0001
Previous upper GI bleeding 1.88 1.17–3.00 0.008
HCC presence 2.57 1.69–3.92 \0.0001
Diuretics use 1.50 0.99–2.27 0.055
Panel B
Previous PVT 7.42 3.90–14.12 \0.0001
Child–Pugh B ? C 2.72 1.75–4.23 \0.0001
HCC presence 2.14 1.35–3.39 0.010
Previous upper GI bleeding 1.75 1.05–2.93 0.030
Age 1.02 1.00–1.04 0.012
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